Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure

Am J Cardiol. 2004 Jul 15;94(2):237-9. doi: 10.1016/j.amjcard.2004.03.074.


SLV306, a potent neutral endopeptidase (NEP) inhibitor with additional endothelin-converting enzyme (ECE)-inhibitory activity, in doses of 200, 400, and 800 mg reduced pulmonary and right atrial pressures, although there was not a clear dose response. Systemic blood pressure, heart rate, and cardiac output were unaffected. SLV306 increased plasma natriuretic peptides and big endothelin-1 levels in a dose-dependent manner, confirming NEP and ECE inhibition. The combined inhibition of NEP and ECE may be useful in heart failure by reducing right and left cardiac filling pressures.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aspartic Acid Endopeptidases / antagonists & inhibitors*
  • Benzazepines / administration & dosage*
  • Blood Pressure / drug effects
  • Cardiac Output / drug effects
  • Endothelin-Converting Enzymes
  • Female
  • Heart Failure / physiopathology*
  • Heart Rate / drug effects
  • Humans
  • Male
  • Metalloendopeptidases
  • Middle Aged
  • Neprilysin / antagonists & inhibitors*
  • Pulmonary Artery / physiology*
  • Pulmonary Wedge Pressure / drug effects*


  • Benzazepines
  • SLV 306
  • Aspartic Acid Endopeptidases
  • Metalloendopeptidases
  • Neprilysin
  • Endothelin-Converting Enzymes